The estimated Net Worth of Mark J Enyedy is at least $24.1 Milion dollars as of 2 February 2024. Mr. Enyedy owns over 51,234 units of Immunogen stock worth over $18,884,705 and over the last 10 years he sold IMGN stock worth over $1,297,634. In addition, he makes $3,917,560 as President, Chief Executive Officer a Director at Immunogen.
Mark has made over 8 trades of the Immunogen stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 51,234 units of IMGN stock worth $1,600,550 on 2 February 2024.
The largest trade he's ever made was exercising 3,119,375 units of Immunogen stock on 2 August 2023 worth over $15,066,581. On average, Mark trades about 82,867 units every 64 days since 2014. As of 2 February 2024 he still owns at least 604,504 units of Immunogen stock.
You can see the complete history of Mr. Enyedy stock trades at the bottom of the page.
Mark J. Enyedy J.D. serves as President, Chief Executive Officer, Director of the Company. Prior to joining ImmunoGen, he served in various executive capacities at Shire PLC, a pharmaceutical company, from 2013 to 2016, including as Executive Vice President and Head of Corporate Development from 2014 to 2016, where he led Shire’s strategy, M&A and corporate planning functions and provided commercial oversight of Shire’s pre-Phase 3 portfolio. Prior to joining Shire, he served as Chief Executive Officer and a director of Proteostasis Therapeutics, Inc., a biopharmaceutical company, from 2011 to 2013. Prior to joining Proteostasis, he served for 15 years at Genzyme Corporation, a biopharmaceutical company, most recently as President of the Transplant, Oncology, and Multiple Sclerosis divisions. Mr. Enyedy holds a JD from Harvard Law School and practiced law prior to joining Genzyme. Mr. Enyedy is also a director of Akebia Therapeutics, LogicBio Therapeutics, Inc., and The American Cancer Society of Eastern New England. Within the past five years, he also served as a director of Fate Therapeutics, Inc. and Keryx Biopharmaceuticals, Inc.
As the President, Chief Executive Officer a Director of Immunogen, the total compensation of Mark Enyedy at Immunogen is $3,917,560. There are no executives at Immunogen getting paid more.
Mark Enyedy is 56, he's been the President, Chief Executive Officer a Director of Immunogen since 2016. There are 10 older and 6 younger executives at Immunogen. The oldest executive at Immunogen, Inc. is Richard Wallace, 68, who is the Independent Director.
Mark's mailing address filed with the SEC is C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO STREET, SAN RAFAEL, CA, 94901.
Over the last 21 years, insiders at Immunogen have traded over $72,947,831 worth of Immunogen stock and bought 303,125 units worth $974,603 . The most active insiders traders include Biochem Incshire Pharmaceut..., Capital, L.P.Morton Holding... a Mark J Enyedy. On average, Immunogen executives and independent directors trade stock every 34 days with the average trade being worth of $2,554,057. The most recent stock trade was executed by Stacy Ann Coen on 2 February 2024, trading 14,350 units of IMGN stock currently worth $448,294.
immunogen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics with its proprietary antibody-drug conjugate (adc) technology. the company's lead product candidate, mirvetuximab soravtansine, is a potential treatment for folate receptor α-positive ovarian cancers and other solid tumors. leading healthcare companies have licensed rights to use immunogen's technology to develop novel anticancer therapies, and roche's marketed product, kadcyla, utilizes immunogen's adc technology. more information about the company can be found at www.immunogen.com.
Immunogen executives and other stock owners filed with the SEC include: